BMRN Biomarin Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BMRN

Price (delayed)

$88.63

Market cap

$16.72B

P/E Ratio

99.58

Dividend/share

N/A

EPS

$0.89

Enterprise value

$17.05B

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and ...

Highlights
BMRN's P/E is 39% below its last 4 quarters average of 163.2
The net income has grown by 18% year-on-year and by 14% since the previous quarter
BMRN's quick ratio has dropped by 51% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biomarin.com
Peers: RARE SGMO FOLD CPRX

Key stats

What are the main financial stats of BMRN
Market
Shares outstanding
188.68M
Market cap
$16.72B
Enterprise value
$17.05B
Valuations
Price to earnings (P/E)
99.58
Price to book (P/B)
3.37
Price to sales (P/S)
6.88
EV/EBIT
82.83
EV/EBITDA
54.96
EV/Sales
7.05
Earnings
Revenue
$2.42B
EBIT
$205.9M
EBITDA
$310.28M
Free cash flow
$62.57M
Per share
EPS
$0.89
Free cash flow per share
$0.33
Book value per share
$26.29
Revenue per share
$12.88
TBVPS
$33.81
Balance sheet
Total assets
$6.84B
Total liabilities
$1.89B
Debt
$1.09B
Equity
$4.95B
Working capital
$1.78B
Liquidity
Debt to equity
0.22
Current ratio
2.51
Quick ratio
1.45
Net debt/EBITDA
1.07
Margins
EBITDA margin
12.8%
Gross margin
78.7%
Net margin
6.9%
Operating margin
6.5%
Efficiency
Return on assets
2.5%
Return on equity
3.5%
Return on invested capital
3.6%
Return on capital employed
3.6%
Return on sales
8.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BMRN stock price

How has the Biomarin Pharmaceutical stock price performed over time
Intraday
-1.6%
1 week
-3.89%
1 month
3.94%
1 year
-10.53%
YTD
-8.08%
QTD
1.48%

Financial performance

How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$2.42B
Gross profit
$1.9B
Operating income
$158.1M
Net income
$167.65M
Gross margin
78.7%
Net margin
6.9%
The operating income has increased by 32% since the previous quarter and by 6% year-on-year
Biomarin Pharmaceutical's operating margin has increased by 25% from the previous quarter but it has decreased by 8% YoY
The net income has grown by 18% year-on-year and by 14% since the previous quarter
Biomarin Pharmaceutical's gross profit has increased by 18% YoY and by 6% QoQ

Growth

What is Biomarin Pharmaceutical's growth rate over time

Valuation

What is Biomarin Pharmaceutical stock price valuation
BMRN P/E details
P/E
99.58
P/B
3.37
P/S
6.88
EV/EBIT
82.83
EV/EBITDA
54.96
EV/Sales
7.05
BMRN's P/E is 39% below its last 4 quarters average of 163.2
Biomarin Pharmaceutical's EPS has increased by 17% YoY and by 16% QoQ
The stock's price to book (P/B) is 16% less than its 5-year quarterly average of 4.0 and 6% less than its last 4 quarters average of 3.6
The equity has grown by 8% YoY
BMRN's price to sales (P/S) is 17% less than its 5-year quarterly average of 8.3 and 9% less than its last 4 quarters average of 7.6
The revenue has grown by 15% YoY and by 4.7% from the previous quarter

Efficiency

How efficient is Biomarin Pharmaceutical business performance
Biomarin Pharmaceutical's ROIC has increased by 24% from the previous quarter and by 20% YoY
Biomarin Pharmaceutical's return on sales has increased by 18% QoQ and by 8% YoY
The ROE has grown by 13% from the previous quarter and by 13% YoY
BMRN's return on assets is up by 9% since the previous quarter and by 9% year-on-year

Dividends

What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BMRN.

Financial health

How did Biomarin Pharmaceutical financials performed over time
BMRN's quick ratio has dropped by 51% year-on-year
The company's current ratio fell by 46% YoY
The debt is 78% smaller than the equity
The equity has grown by 8% YoY
BMRN's debt to equity is down by 8% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.